July 18, 2019Open Access

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165

Key Points

Key points are not available for this paper at this time.

Abstract

appears differentiated from all other reported JAK inhibitors and has been advanced as the first pseudokinase-directed therapeutic in clinical development as an oral treatment for autoimmune diseases.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Wrobleski et al. (Thu,) studied this question.

synapsesocial.com/papers/69f83530f0eec1c546a62894 https://doi.org/https://doi.org/10.1021/acs.jmedchem.9b00444

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1One-Pot Synthesis of Hybrid Macrocyclic Pentamers with Variable Functionalizations around the Periphery2011 · 36 citations
2The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis2017 · 94 citations
3Jak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis1998 · 916 citations
4tyk2, prototype of a novel class of non-receptor tyrosine kinase genes.1990 · 329 citations
5Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis2006 · 1,845 citations

Bookmark

View Full Paper